Order Article Reprints

Kurata Y, Mouri A, Imai H, Endo S, Tsukamoto K, Masaki K, Hashimoto K, Miura Y, Shiono A, Yamaguchi O, et al. Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study. Medicina. 2025; 61(6):994. https://doi.org/10.3390/medicina61060994

Kurata, Yuhei, Atsuto Mouri, Hisao Imai, Satoshi Endo, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, and et al. 2025. "Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study" Medicina 61, no. 6: 994. https://doi.org/10.3390/medicina61060994

Kurata, Y., Mouri, A., Imai, H., Endo, S., Tsukamoto, K., Masaki, K., Hashimoto, K., Miura, Y., Shiono, A., Yamaguchi, O., Nakagawa, J., Kaira, K., Kobayashi, K., & Kagamu, H. (2025). Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study. Medicina, 61(6), 994. https://doi.org/10.3390/medicina61060994